Generate a tailored SOP for Dr. Sunil Shaunak. Improve your application with a focused, well-structured draft.
Professor Sunil Shaunak is an Emeritus Professor in Infectious Diseases at Imperial College London. He has made significant contributions to the development of cost-effective new medicines for diseases such as Hepatitis C, Shigella, Leishmaniasis, and HIV. He co-founded the Imperial spinout PolyTherics in 2001, which was renamed Abzena and listed on London's AIM market in 2014. Under his guidance, Abzena has focused on the development of biopharmaceutical products in the UK and has advanced the ThioBridge technology, which involves protein disulfide bridge-based conjugation of drugs, facilitating the creation of potent antibody-drug conjugates (ADCs) for new medicines. Professor Shaunak has been a strong advocate for equitable global access to affordable medicines, showcasing how university-based innovations can lead to new, useful, and affordable healthcare products. His pioneering work has demonstrated the value of combining university drug discovery with industry drug development, resulting in practical solutions to improve health worldwide. In recognition of his contributions to Infectious Diseases Drug Discovery, he was awarded the OBE in 2023.
Imperial College London • London, United Kingdom
Professor in Infectious Diseases, focusing on drug discovery and development.
Specialisms available in Materials for the Energy Transition or Theory and Simulation of Materials.